GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Valuation Rank

Vicore Pharma Holding AB (STU:6Y4) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Vicore Pharma Holding AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Valuation Rank
Comparable Companies
OSTO:HNSA OSTO:BINV OSTO:EGTX OSTO:GENO OSTO:XSPRAY OSTO:DMYD B OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
VICO:Sweden 6Y4:Germany
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Website
https://www.vicorepharma.com
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.